title: Gaseous nitric oxide reduces influenza infectivity in vitro.
abstract: Gaseous nitric oxide (gNO) is an approved vasodilator drug for inhalation up to a maximum dose of 80 ppm. While gNO has been shown, in vitro, to be an effective antibacterial agent (at 160 ppm), NO-donor compounds have been shown to inhibit a variety of viruses at varying stages of replication. This research was done in order to determine whether gNO at 80 or 160 ppm possesses an antiviral effect on influenza viruses. Three strains of influenza (A and B) were exposed to gNO for up to 180 min, before and after infection of MDCK cells. In search for possible mechanism of antiviral action, Neuraminidase (NA) inhibition assay of H1N1 that was exposed to gNO was performed. Results show that when virions were exposed to gNO prior to infection a complete inhibition of infectivity was achieved for all three strains. Post infection exposure of influenza with gNO resulted in about 30% inhibition of infectivity. Further testing showed that when eliminating the pH effect by exposing a dried virus to gNO, 90% inhibition was found after 2h exposure. NA activity, of whole dried H1N1 virus, was found to be inhibited by gNO (80%). These results suggest that 80 and 160 ppm gNO have a time dependent antiviral effect on influenza strains of viruses during various stages of cellular infection, which are not due to concomitant changes in pH in the surrounding milieu. Viral NA inhibition by gNO was shown and may be responsible for this antiviral effect.
authors.affiliation: Department of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Gilly
authors.initials: G
authors.lastname: Regev-Shoshani
authors.forename: Selvarani
authors.initials: S
authors.lastname: Vimalanathan
authors.forename: Bevin
authors.initials: B
authors.lastname: McMullin
authors.forename: Jeremy
authors.initials: J
authors.lastname: Road
authors.forename: Yossef
authors.initials: Y
authors.lastname: Av-Gay
authors.forename: Chris
authors.initials: C
authors.lastname: Miller
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004285:Dogs; D005740:Gases / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007251:Influenza, Human / Q000517:prevention & control* / Q000821:virology; D029521:Alphainfluenzavirus / Q000472:pathogenicity / Q000502:physiology*; D029524:Betainfluenzavirus / Q000472:pathogenicity / Q000502:physiology*; D061985:Madin Darby Canine Kidney Cells; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D009569:Nitric Oxide / Q000494:pharmacology*; D009976:Orthomyxoviridae Infections / Q000517:prevention & control* / Q000821:virology; D015203:Reproducibility of Results; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents; D005740:Gases; D009569:Nitric Oxide; D009439:Neuraminidase
references.citation: Immunology. 2000 Nov;101(3):300-8
references.pmid: 11106932
references.citation: Anal Biochem. 1982 Oct;126(1):131-8
references.pmid: 7181105
references.citation: IUBMB Life. 1999 Jul;48(1):25-31
references.pmid: 10791912
references.citation: Nitric Oxide. 2006 Feb;14(1):21-9
references.pmid: 16188471
references.citation: J Virol. 1999 Oct;73(10):8880-3
references.pmid: 10482647
references.citation: J Allergy Clin Immunol. 2009 Sep;124(3):551-7
references.pmid: 19541350
references.citation: Nitric Oxide. 2005 May;12(3):129-40
references.pmid: 15797841
references.citation: J Clin Invest. 1997 Oct 1;100(7):1760-7
references.pmid: 9312175
references.citation: J Biol Chem. 1991 Mar 5;266(7):4244-50
references.pmid: 1847917
references.citation: J Virol. 2005 Feb;79(3):1966-9
references.pmid: 15650225
references.citation: Nitric Oxide. 2009 Feb;20(1):16-23
references.pmid: 18789393
references.citation: N Engl J Med. 2005 Sep 29;353(13):1363-73
references.pmid: 16192481
references.citation: Immunol Today. 1991 Mar;12(3):A17-21
references.pmid: 1712593
references.citation: Antimicrob Agents Chemother. 1980 May;17(5):865-70
references.pmid: 7396473
references.citation: Respir Care. 2005 Nov;50(11):1451-6
references.pmid: 16253152
references.citation: Antimicrob Agents Chemother. 2010 Jan;54(1):273-9
references.pmid: 19884372
references.citation: Med Microbiol Immunol. 2004 May;193(2-3):91-100
references.pmid: 14513374
references.citation: JAMA. 2009 Mar 11;301(10):1034-41
references.pmid: 19255110
references.citation: World J Surg. 2004 Mar;28(3):301-6
references.pmid: 14961192
references.citation: Immunity. 1999 Jan;10(1):21-8
references.pmid: 10023767
references.citation: Mayo Clin Proc. 2010 Mar;85(3):257-73
references.pmid: 20118381
references.citation: Antimicrob Agents Chemother. 2005 Mar;49(3):1209-12
references.pmid: 15728930
references.citation: Clin Sci (Lond). 2001 Apr;100(4):395-400
references.pmid: 11256977
references.citation: J Clin Invest. 1993 Jun;91(6):2446-52
references.pmid: 8390481
references.citation: Virology. 1998 Sep 1;248(2):284-94
references.pmid: 9721237
references.citation: J Med Virol. 2005 Sep;77(1):89-95
references.pmid: 16032750
references.citation: J Virol. 1998 Jun;72(6):4547-51
references.pmid: 9573217
references.citation: J Appl Microbiol. 2001 Apr;90(4):648-52
references.pmid: 11309079
references.citation: MMWR Morb Mortal Wkly Rep. 2011 Sep 16;60(36):1239-42
references.pmid: 21918493
references.citation: Int J Antimicrob Agents. 2005 Jul;26(1):85-7
references.pmid: 15955674
references.citation: JAMA. 2003 Jan 8;289(2):179-86
references.pmid: 12517228
references.citation: J Virol. 1995 Feb;69(2):910-5
references.pmid: 7529336